The Almac Group has today announced the release of its 2024 Sustainability Report which outlines Almac’s ongoing commitment to their people, the planet and the communities where the Group operates, ...
A lengthy treatment process, coupled with weighty risks for recipients to consider, has resulted in plodding adoption of ...
Clinical services organizations help pharmaceutical manufacturers manage growing regulatory complexities, high development ...
Despite the disease’s prevalence, endometriosis remains misunderstood, and research into drugs that might treat it draws scant funding — problems that have deep roots.
The biotech disclosed Friday plans to terminate a Phase 2 study testing azelaprag with tirzepatide for weight loss following ...
A Johns Hopkins surgeon, Marty Makary also serves as a board member or adviser to several companies, including one that ...
At the center of a new licensing deal is an experimental medicine, PTC518, which is currently being tested in a roughly ...
Results from the head-to-head study showed treatment with Zepbound resulted in 47% greater relative weight loss than Wegovy, ...
The two partners disclosed study results supporting an approval application for their drug dato-dxd. Elsewhere, Agenus cut ...
The company, which raised $84 million, sees validation of its GIP-blocking approach to weight loss in Amgen's recent MariTide ...
Novo will pay $200 million to gain control of the protein manufacturing factory. Elsewhere, Roivant dropped a drug program ...
The expansion of a newly acquired facility in Wisconsin is Lilly’s largest U.S. manufacturing investment outside of Indiana ...